Summary
Medtronic plc (MDT) reported a strong second quarter for fiscal year 2026, with net sales increasing by 7% to $8.96 billion and diluted earnings per share rising to $1.07 from $0.99 in the prior year period. The company demonstrated robust revenue growth across most of its key segments, including Cardiovascular, Neuroscience, and Medical Surgical, driven by strong product adoption and positive currency impacts. For the first six months of the fiscal year, net sales grew 8% year-over-year to $17.54 billion, with diluted EPS of $1.87. Free cash flow remained solid, totaling $1.04 billion for the first six months, indicating effective operational management. While the company navigated an evolving global economic landscape, including tariff impacts and geopolitical uncertainties, its diversified portfolio and strategic initiatives, such as the planned separation of its Diabetes business, position it for continued performance. Management highlighted investments in R&D and efforts to manage SG&A expenses, supporting long-term growth and shareholder value. The company's financial position remains strong, with ample liquidity to fund operations and strategic initiatives.
Financial Highlights
53 data points| Revenue | $8.96B |
| Cost of Revenue | $3.06B |
| Gross Profit | $5.90B |
| SG&A Expenses | $2.96B |
| Operating Income | $1.69B |
| Net Income | $1.37B |
| EPS (Basic) | $1.07 |
| EPS (Diluted) | $1.07 |
| Shares Outstanding (Basic) | 1.28B |
| Shares Outstanding (Diluted) | 1.29B |
Key Highlights
- 1Net sales for the quarter increased 7% to $8.96 billion, and 8% for the six-month period to $17.54 billion, driven by broad-based growth across segments.
- 2Diluted EPS rose to $1.07 for the quarter, up from $0.99 in the prior year, reflecting improved profitability.
- 3Cardiovascular segment showed strong performance with 11% net sales growth for the quarter, driven by TAVR and cardiac rhythm management products.
- 4Neuroscience segment sales increased 5% for the quarter, supported by growth in Neuromodulation and Cranial & Spinal Technologies.
- 5Free cash flow for the first six months of the fiscal year was $1.04 billion, demonstrating strong cash generation.
- 6Medtronic announced its intent to separate its Diabetes business into a new independent company, expected to be completed within 18 months.
- 7The company provided an updated outlook on tariff impacts, estimating a pre-tax net tariff impact of $185 million in fiscal year 2026.